All In Biotech

Drug Trial Radar · NCT06469879

A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients

A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2450 Combined With Anlotinib as Maintenance Therapy in Patients With Limited-stage Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jul 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 358 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

358

Planned (sponsor's estimate)

Start

Sep 2024

Primary completion

Sep 2026

Study completion Sep 2026

Sponsor

Sponsor type
Industry
First posted
Jun 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of TQB2450 in combination with anlotinib as maintenance therapy in patients with limited-stage small cell lung cancer who have not progressed after chemoradiotherapy.

Conditions

  • Small Cell Lung Cancer Limited Stage

Interventions

  • TQB2450+AnlotinibDrug

    TQB2450 injection test group, 1200 mg/time, strength: 600mg/20 mL, intravenous drip, day 1, every 3 weeks. Anlotinib hydrochloride capsules: 8 mg/time, strength: 10mg/capsule, 8mg/capsule, 6mg/capsule., 1 time a day (QD), continuous use for 2 weeks and stop for 1 week. TQB2450 Injection Placebo (control group): 0 mg/time, strength: 0mg/20 mL, Intravenous Drip, Day 1, every 3 weeks. Anlotinib hydrochloride capsule placebo: 0 mg/time, strength: 0mg/capsule, 1 time a day (QD), continuous use for 2 weeks and stop for 1 week.

  • TQB2450 placebo + Anlotinib placeboDrug

    No drug substance is contained

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) evaluated by the Independent Review Committee (IRC)Time frame: up to 33 months

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chest Hospital, Capital Medical University

    Beijing, China

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, China

  • Guangxi Medical University Cancer Hospital

    Nanjing, Guangxi, China

  • Tangshan People's Hospital

    Tangshan, Hebei, China

  • Harbin Medical University cancer hospital

    Harbin, Heilongjiang, China

  • AnYang Tumor Hospital

    Anyang, Henan, China

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • Shanxi Provincial Cancer Hpspital

    Taiyuan, Shanxi, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China

  • The Second People's Hospital of Neijiang

    Neijiang, Sichuan, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.